Heavy weight! Application for conditional marketing of kangxinuo biological recombinant new coronavirus vaccine accepted

In February 24th, Conchino bio Co. announced that the recombinant New Coronavirus vaccine (type 5 adenovirus vector) ("Ad5-nCoV") developed jointly by the company and the Institute of biomedical engineering of the Academy of Military Medical Sciences of the Academy of Military Sciences. The commodity is called Kwisa. ™) On February 21 this year, the company formally submitted an application for conditional listing to the State Food and Drug Administration and accepted it.

Global multicenter phase III clinical studies have been carried out in Pakistan, Mexico, Russia, Chile and Argentina, and more than 40000 transplants and interim data analysis have been completed. The results of data analysis in phase 3 clinical trial of Ad5 ncov showed that the overall protective effect of the vaccine on all symptoms was 65.28% after 28 days of single dose vaccination, and 68.83% after 14 days of single dose vaccination. The protective effects of the vaccine on severe cases were 90.07% after 28 days of single dose vaccination and 95.47% after 14 days of single dose vaccination.

The results of data analysis in the phase III clinical trial of Ad5 ncov showed that the overall protective effect of the vaccine on all symptoms was 65.28% after 28 days of single dose vaccination, and 68.83% after 14 days of single dose vaccination. The protective effects of the vaccine on severe cases were 90.07% after 28 days of single dose vaccination and 95.47% after 14 days of single dose vaccination.

Ad5-nCoV protection effectiveness data reached the relevant WHO standards and the China National Drug Administration (NMPA) issued the "New Coronavirus preventive vaccine clinical evaluation guidelines (Trial)" in the relevant standards.

On February 10, Connaught announced that according to the interim results of the phase 3 clinical trial of Ad5 ncov, Ad5 ncov was authorized for emergency use by the Federal Health Risk Protection Commission of Mexico on February 9 local time for adults over 18 years old; on February 16, Ad5 ncov was authorized for emergency use by the drug Administration of Pakistan.